Drug-eluting stents for the treatment of coronary artery disease

a list price of £1,500 (BMS equivalent: Janis). • The DES Xience V (Guidant Ltd) is a polymeric everolimus-eluting stent (EES) with a list price of £1,500 (BMS equivalent: Multi-Link Vision). • The DES Dexamet (Abbott Vascular Devices Ltd) is a polymeric dexamethasone-eluting stent (BMS equivalent: BiodivYsio). Dexamet was originally included in this appraisal but is no longer available in the EU. • The DES Yukon (Kiwimed Ltd) is a non-polymeric stent that can be coated with any drug to be eluted and has a list price of £650. 3.5 As list prices are not commonly used for procuring devices in the NHS, updated prices of DESs and BMSs were sought from the NHS Purchasing and Supply Agency. Procurement of devices is complex and it should be noted that the prices for DES and BMS are driven by a number of factors including the: market conditions at the time of contracting; contract period; renewal date for the procurement arrangements (contracts are usually updated annually and the most recent contracts show significant decreases in the prices of DESs); volume commitment; period commitment; combination of period and volume commitment; product rationalisation or standardisation; retrospective threshold discounts (for example, free set quantities of
